ES2477877T3 - Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos - Google Patents

Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos Download PDF

Info

Publication number
ES2477877T3
ES2477877T3 ES08785441.0T ES08785441T ES2477877T3 ES 2477877 T3 ES2477877 T3 ES 2477877T3 ES 08785441 T ES08785441 T ES 08785441T ES 2477877 T3 ES2477877 T3 ES 2477877T3
Authority
ES
Spain
Prior art keywords
hydroxy vitamin
mammals
muscle mass
increase muscle
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08785441.0T
Other languages
English (en)
Other versions
ES2477877T5 (es
Inventor
Thau Kiong Chung
Benito Averion Oliveros
Francisco Feranil Penalba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39874890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2477877(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of ES2477877T3 publication Critical patent/ES2477877T3/es
Application granted granted Critical
Publication of ES2477877T5 publication Critical patent/ES2477877T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de 25-hidroxi vitamina D3 para promover de forma no terapéutica la miogénesis en un mamífero al administrar de forma prenatal una cantidad suficiente de 25-hidroxi vitamina D3 al mamífero durante el período de hiperplasia de fibras musculares.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES08785441.0T 2007-08-07 2008-08-07 Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos Active ES2477877T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07015458 2007-08-07
EP07015458 2007-08-07
PCT/EP2008/006537 WO2009019027A1 (en) 2007-08-07 2008-08-07 Use of 25-hydroxy vitamin d3 to increase muscle mass in mammals

Publications (2)

Publication Number Publication Date
ES2477877T3 true ES2477877T3 (es) 2014-07-18
ES2477877T5 ES2477877T5 (es) 2018-09-21

Family

ID=39874890

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08785441.0T Active ES2477877T5 (es) 2007-08-07 2008-08-07 Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos

Country Status (9)

Country Link
US (1) US20110124608A1 (es)
EP (1) EP2173356B2 (es)
JP (1) JP5509502B2 (es)
KR (1) KR101503948B1 (es)
CN (1) CN101778636B (es)
DK (1) DK2173356T4 (es)
ES (1) ES2477877T5 (es)
PL (1) PL2173356T5 (es)
WO (1) WO2009019027A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1011245B1 (pt) * 2009-06-11 2020-03-24 Dsm Ip Assets B.V. Uso de trigonelina como um estimulante muscular.
CN107232417B (zh) * 2017-06-28 2018-09-25 广西商大科技股份有限公司 一种母猪六段式营养全价饲料和投料方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
DK1516540T3 (da) * 2003-09-22 2012-11-26 Dsm Ip Assets Bv Anvendelse af vitamin D-forbindelser
EP1917071B1 (en) * 2005-08-18 2014-01-08 DSM IP Assets B.V. Use of 25-hydroxy vitamin d3 to improve male animal fertility
WO2007047327A2 (en) * 2005-10-12 2007-04-26 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
JP5395438B2 (ja) * 2005-11-25 2014-01-22 ディーエスエム アイピー アセッツ ビー．ブイ． 動物の活力を改良するための２５−ヒドロキシビタミンｄ３の使用

Also Published As

Publication number Publication date
EP2173356A1 (en) 2010-04-14
JP5509502B2 (ja) 2014-06-04
EP2173356B1 (en) 2014-04-16
CN101778636A (zh) 2010-07-14
EP2173356B2 (en) 2018-05-02
US20110124608A1 (en) 2011-05-26
KR20100053549A (ko) 2010-05-20
PL2173356T3 (pl) 2014-09-30
PL2173356T5 (pl) 2018-11-30
WO2009019027A1 (en) 2009-02-12
KR101503948B1 (ko) 2015-03-18
DK2173356T3 (da) 2014-07-07
CN101778636B (zh) 2012-11-28
JP2010535727A (ja) 2010-11-25
DK2173356T4 (en) 2018-08-13
ES2477877T5 (es) 2018-09-21

Similar Documents

Publication Publication Date Title
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ECSP056082A (es) Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa
IT1392903B1 (it) Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
AR062857A1 (es) Crema para bebidas
CR10987A (es) Composiciones dispersables en agua y los metodos para utilizar las composiciones dispersables en agua
EP2299895A4 (en) IN VIVO CAMERA WITH SEVERAL SOURCES FOR ILLUMINATING TISSUE IN DIFFERENT DISTANCES
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
UY28509A1 (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
BRPI0815821A2 (pt) Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico.
CR6964A (es) Combinacion de agonistas de gaba einhibidores de sorbitol-deshidrogenasa
ES2517491T3 (es) Estabilizador de los vasos linfáticos
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
ES2477877T3 (es) Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos
MA33022B1 (fr) Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil
DOP2010000361A (es) Dronedarona para la prevencion de la cardioversion
ES2526913T3 (es) Composición farmacéutica que contiene neurotoxina 2 botulínica
ES2544780T3 (es) Metadoxina para su uso como inhibidor de fibrosis hepática
ES2533046T3 (es) Oleíl-fosfocolina
ES2486844T3 (es) Sustancia que presenta propiedad antidepresiva
AR066108A1 (es) Utilizacion de 4- ciclopropilmetoxi -n- (3,5- dicloro-1 oxido- piridin- 4-il) -5-(metoxi) piridin-2- carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
ITMI20051446A1 (it) Composizione per ridurre i lipid nel sangue